Cary Street Partners Asset Management’s Acadia Pharmaceuticals ACAD Stock Holding History

Cary Street Partners Asset Management’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-16,840	Closed	-$17K	–	155
2021 Q1	$17K	Sell	16,840 -11,695	-41%	-$515K	﹤0.01%	177
2020 Q4	$642K	Buy	+28,535	New	+$1.42M	0.19%	106

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return

Fred Alger Management New York $30B AUM 76.99% 1-Year Est. Return

Cary Street Partners Asset Management's ACAD Position: Q2 2021 in Review

Cary Street Partners Asset Management sold out of Acadia Pharmaceuticals (ACAD) in Q2 2021, closing a stake of 16,840 shares — an estimated $17K sold.

Cary Street Partners Asset Management first reported a position in ACAD in Q4 2020 and held it in 2 quarters. The position peaked at $642K in Q4 2020. 245 funds tracked by Wall St. Rank hold ACAD as of Q2 2021.

Cary Street Partners Asset Management reported no remaining Acadia Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
Cary Street Partners Asset Management sold 16,840 Acadia Pharmaceuticals shares in Q2 2021, an estimated $17K.
Cary Street Partners Asset Management first reported a position in Acadia Pharmaceuticals in Q4 2020 and held it in 2 quarters.
Cary Street Partners Asset Management's Acadia Pharmaceuticals position peaked at $642K in Q4 2020.
245 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2021.

Based on Cary Street Partners Asset Management's 13F filing for Q2 2021, filed 16 Aug 2021.